26 August 2025
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
AGM Statement
CRISM Therapeutics (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is holding its Annual General Meeting ("AGM") today at 11am at the office of Fieldfisher LLP. At the meeting, CRISM's Non-Executive Chair, Dr Nermeen Varawalla will make the following statement:
"This meeting marks our first AGM since CRISM Therapeutics was admitted to AIM following the reverse takeover of Amur Minerals in May 2024. This transformative transaction has provided us with the platform to deliver the significant progress we have made since becoming a listed entity. Our strategy has delivered some key operational achievements during 2025.
"In June we successfully submitted our Clinical Trial Authorisation application to the MHRA for our registration grade Phase 2 study of irinotecan ChemoSeed in patients with resectable glioblastoma, a critical milestone in the technology's development. We recently announced the initiation of production of a clinical batch of ChemoSeed under Good Manufacturing Practice with ProMed Pharma. Our progress is being supported by a recent fundraise, raising £874,021 in June and I thank all shareholders for their continued support.
"The potential of ChemoSeed extends beyond a single application and was validated by a grant award from Innovate UK in March to support the pre-clinical development of ChemoSeed for prostate cancer, representing a second indication and significant market opportunity for our technology.
"In order to achieve our objectives, we must attract, retain and incentivise the best people. To that end, we have established an Enterprise Management Incentives Option Plan, to ensure our team is motivated and aligned with our long-term goals, which shareholders are voting on today.
"Going forward we are focused on gaining trial approval from the MHRA in glioblastoma and progressing towards dosing our first patients in early 2026. Additionally, we will continue to seek further validation for our novel delivery method and are confident that ChemoSeed has the potential to transform treatment for patients with solid-tumour cancers."
-Ends-
Enquiries:
| Company |
Nomad and Broker |
Financial PR |
| CRISM Therapeutics Corporation |
S.P. Angel Corporate Finance LLP |
Burson Buchanan |
| Andrew Webb, CEO Chris McConville, CSO |
Richard Morrison Vadim Alexandre Adam Cowl |
Mark Court / Jamie Hooper CRISM@buchanancomms.co.uk |
| via Burson Buchanan |
+44 (0) 20 3470 0470 |
+44 (0) 20 7466 5000 |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
For more information please visit: https://www.crismtherapeutics.com/
The Company's LEI is 213800XFW6MKVCHHPW88.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.